|
1) Misu H, Takamura T, Matsuzawa N, et al. Genes involved in oxidative phosphorylation are coordinately upregulated with fasting hyper-glycaemia in livers of patients with type 2 diabetes. Diabetologia. 2007; 50: 268-77
|
|
|
|
2) Takamura T, Sakurai M, Ota T, et al. Genes for systemic vascular complications are differentially expressed in the livers of type 2 diabetic patients. Diabetologia. 2004; 47: 638-47
|
|
|
|
|
|
3) Auberger P, Falquerho L, Contreres JO, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell. 1989; 58: 631-40
|
|
|
|
|
|
4) Goustin AS, Abou-Samra AB. The “thrifty" gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signal. 2011; 23: 980-90
|
|
|
|
|
|
5) Mathews ST, Chellam N, Srinivas PR, et al. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol. 2000; 164: 87-98
|
|
|
|
|
|
6) Mori K, Emoto M, Yokoyama H, et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care. 2006; 29: 468
|
|
|
|
|
|
7) Westenfeld R, Jahnen-Dechent W, Ketteler M. Vascular calcification and fetuin-A deficiency in chronic kidney disease. Trends Cardiovasc Med. 2007; 17: 124-8
|
|
|
|
|
|
8) Oike Y, Yasunaga K, Suda T. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. Int J Hematol. 2004; 80: 21-8
|
|
|
|
|
9) Oike Y, Yasunaga K, Ito Y, et al. Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration. Proc Natl Acad Sci U S A. 2003; 100: 9494-9
|
|
|
|
|
|
10) Oike Y, Ito Y, Maekawa H, et al. Angiopoietin-related growth factor (AGF) promotes angio-genesis. Blood. 2004; 103: 3760-5
|
|
|
|
|
|
11) Oike Y, Akao M, Yasunaga K, et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med. 2005; 11: 400-8
|
|
|
|
|
|
12) Kadomatsu T, Tabata M, Oike Y. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J. 2011; 278: 559-64
|
|
|
|
|
|
13) Misu H, Takamura T, Takayama H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010; 12: 483-95
|
|
|
|
|
|
14) Yang SJ, Hwang SY, Choi HY, et al. Serum selenoprotein p levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab. 2011; 96: E1325-9
|
|
|
|
|
|
15) Burk RF, Hill KE. Selenoprotein P: an extra-cellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr. 2005; 25: 215-35
|
|
|
|
|
|
16) Carlson BA, Novoselov SV, Kumaraswamy E, et al. Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J Biol Chem. 2004; 279: 8011-7
|
|
|
|
|
|
17) Hill KE, Zhou J, McMahan WJ, et al. Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem. 2003; 278: 13640-6
|
|
|
|
|